Patent intelligence · US
US 10624887
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
Patent details — US 10624887
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 21, 2020
- Expiration
- Apr 16, 2040
- Applicant
- Relmada Therapeutics, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K31/485, A61K9/0053, A61K9/006
Quick answer
US 10624887 (Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol) is held by Relmada Therapeutics, Inc.. Status: granted. Granted Apr 21, 2020. Expires Apr 16, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Relmada Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/485, A61K9/0053, A61K9/006, A61K9/1635, A61K9/1676
More from Relmada Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11607407
Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
granted -
US 9855226
d-methadone for the treatment of psychiatric symptoms
granted -
US 9468611
d-Methadone for the treatment of psychiatric symptoms
granted -
US 9364430
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
granted -
US 9125833
Multimodal abuse resistant and extended release opioid formulations
granted -
US 8329744
Methods of preventing the serotonin syndrome and compositions for use thereof
granted
Related coverage
Frequently asked questions
What is US patent 10624887?
US 10624887 (Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol) is held by Relmada Therapeutics, Inc.. Status: granted. Granted Apr 21, 2020. Expires Apr 16, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10624887?
Relmada Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 10624887 expire?
Our index shows an expiration date of Apr 16, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.